Host: The Japanese Pharmacological Society
Name : The 95th Annual Meeting of the Japanese Pharmacological Society
Number : 95
Location : Fukuoka
Date : March 07, 2022 - March 09, 2022
New approaches methodologies (NAMs) have been developed to predict adverse events in humans more accurately. In vitro methods, such as human iPS cell technology, are expected to accelerate the efficiency of drug development and ensure the patients' safety and speed-up of the review process. We have evaluated the iPSC-based tools to assess safety and effectiveness of chemicals from the viewpoint of regulatory science. Based on the current COVID-19 pandemic situation and animal alternative methods, we have made various iPSC models, such as cardiomyocytes, blood-brain barrier, and intestine, to evaluate the effects of COVID-19 drugs. Here we would like to summarize the current status and future perspectives of iPSC-based system for COVID-19 in drug development.
